$0.43
1.43%
Nasdaq, Sep 29, 01:21 pm EDT. Market open.
ISIN
US71715X2036
Symbol
PMCB

PharmaCyte Biotech Inc Stock price

$0.42
-0.10 18.47% 1M
-0.25 37.42% 6M
-0.30 42.00% YTD
-0.56 57.15% 1Y
-1.73 80.47% 3Y
-2.80 86.96% 5Y
-46.08 99.10% 10Y
-314.58 99.87% 20Y
Nasdaq, Closing price Mon, Sep 28 2026
-0.02 4.78%
ISIN
US71715X2036
Symbol
PMCB
Industry

Is PharmaCyte Biotech Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
$4.5m
Enterprise Value
$-32.6m
Net debt
positive
Cash
$30.5m
Shares outstanding
10.7m
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
6.3
P/B
0.1
Financial Health
Equity Ratio
74.8%
Return on Equity
-66.3%
ROCE
-15.2%
ROIC
-94.5%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | -
EBITDA
-
EBIT
$-5.5m
Net Income
$-20.6m
Free Cash Flow
$-3.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-
EBIT
-38.1%
Net Income
-486.1%
Free Cash Flow
14.4%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$-1.9
FCF per Share
$-0.4
Short interest
0.7%
Employees
2
Rev per Employee
$0.0

PharmaCyte Biotech Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a PharmaCyte Biotech Inc forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a PharmaCyte Biotech Inc forecast:

Hold
50%
Sell
50%

Financial data from PharmaCyte Biotech Inc

Jul '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.11 5.11
16% 16%
-
- Research and Development Expense 0.36 0.36
18% 18%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -5.46 -5.46
38% 38%
-
Net Profit -21 -21
486% 486%
-

In millions USD.

Don't miss a Thing! We will send you all news about PharmaCyte Biotech Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.

Head office United States
CEO Mr. Silverman
Employees 2
Founded 1996
Website pharmacyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today